• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 与新兴变异株:揭示结构、功能、感染和免疫逃逸机制。

SARS-CoV-2 and Emerging Variants: Unmasking Structure, Function, Infection, and Immune Escape Mechanisms.

机构信息

Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.

出版信息

Front Cell Infect Microbiol. 2022 May 12;12:869832. doi: 10.3389/fcimb.2022.869832. eCollection 2022.

DOI:10.3389/fcimb.2022.869832
PMID:35646741
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9134119/
Abstract

As of April 1, 2022, over 468 million COVID-19 cases and over 6 million deaths have been confirmed globally. Unlike the common coronavirus, SARS-CoV-2 has highly contagious and attracted a high level of concern worldwide. Through the analysis of SARS-CoV-2 structural, non-structural, and accessory proteins, we can gain a deeper understanding of structure-function relationships, viral infection mechanisms, and viable strategies for antiviral therapy. Angiotensin-converting enzyme 2 (ACE2) is the first widely acknowledged SARS-CoV-2 receptor, but researches have shown that there are additional co-receptors that can facilitate the entry of SARS-CoV-2 to infect humans. We have performed an in-depth review of published papers, searching for co-receptors or other auxiliary membrane proteins that enhance viral infection, and analyzing pertinent pathogenic mechanisms. The genome, and especially the spike gene, undergoes mutations at an abnormally high frequency during virus replication and/or when it is transmitted from one individual to another. We summarized the main mutant strains currently circulating global, and elaborated the structural feature for increased infectivity and immune evasion of variants. Meanwhile, the principal purpose of the review is to update information on the COVID-19 outbreak. Many countries have novel findings on the early stage of the epidemic, and accruing evidence has rewritten the timeline of the outbreak, triggering new thinking about the origin and spread of COVID-19. It is anticipated that this can provide further insights for future research and global epidemic prevention and control.

摘要

截至 2022 年 4 月 1 日,全球已确认超过 4.68 亿例 COVID-19 病例和超过 600 万人死亡。与普通冠状病毒不同,SARS-CoV-2 具有高度传染性,引起了全球高度关注。通过对 SARS-CoV-2 结构、非结构和辅助蛋白的分析,我们可以更深入地了解结构-功能关系、病毒感染机制和可行的抗病毒治疗策略。血管紧张素转换酶 2(ACE2)是第一个被广泛认可的 SARS-CoV-2 受体,但研究表明,还有其他辅助受体可以促进 SARS-CoV-2 进入感染人类。我们对已发表的论文进行了深入回顾,寻找增强病毒感染的辅助受体或其他辅助膜蛋白,并分析相关的发病机制。基因组,特别是刺突基因,在病毒复制和/或从一个个体传播到另一个个体时,以异常高的频率发生突变。我们总结了目前全球流行的主要突变株,并详细阐述了增加变体感染性和免疫逃逸的结构特征。同时,综述的主要目的是更新关于 COVID-19 爆发的信息。许多国家在疫情早期有新的发现,不断增加的证据改写了疫情的时间表,引发了对 COVID-19 起源和传播的新思考。预计这将为未来的研究和全球疫情防控提供进一步的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37d8/9134119/eb4a80192fc6/fcimb-12-869832-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37d8/9134119/64d498b8548e/fcimb-12-869832-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37d8/9134119/e5e17fdec21b/fcimb-12-869832-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37d8/9134119/fefa2c8ed223/fcimb-12-869832-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37d8/9134119/eb4a80192fc6/fcimb-12-869832-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37d8/9134119/64d498b8548e/fcimb-12-869832-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37d8/9134119/e5e17fdec21b/fcimb-12-869832-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37d8/9134119/fefa2c8ed223/fcimb-12-869832-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37d8/9134119/eb4a80192fc6/fcimb-12-869832-g004.jpg

相似文献

1
SARS-CoV-2 and Emerging Variants: Unmasking Structure, Function, Infection, and Immune Escape Mechanisms.SARS-CoV-2 与新兴变异株:揭示结构、功能、感染和免疫逃逸机制。
Front Cell Infect Microbiol. 2022 May 12;12:869832. doi: 10.3389/fcimb.2022.869832. eCollection 2022.
2
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.I型、II型和III型干扰素的抗病毒活性可抵消ACE2的诱导性并限制新型冠状病毒。
mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20.
3
A So-Far Overlooked Secondary Conformation State in the Binding Mode of SARS-CoV-2 Spike Protein to Human ACE2 and Its Conversion Rate Are Crucial for Estimating Infectivity Efficacy of the Underlying Virus Variant.SARS-CoV-2 刺突蛋白与人 ACE2 结合模式中一个迄今被忽视的次要构象状态及其转化率对于评估潜在病毒变体的感染力效力至关重要。
J Virol. 2022 Jul 13;96(13):e0068522. doi: 10.1128/jvi.00685-22. Epub 2022 Jun 8.
4
Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2).新型冠状病毒(SARS-CoV-2)对血管紧张素转换酶2(ACE2)结构识别的遗传变异研究。
J Transl Med. 2020 Aug 24;18(1):321. doi: 10.1186/s12967-020-02486-7.
5
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.SARS-CoV-2 变体 B.1.617.1 (Kappa)、B.1.617.2 (Delta) 和 B.1.618 的细胞进入和免疫逃逸特性。
mBio. 2022 Apr 26;13(2):e0009922. doi: 10.1128/mbio.00099-22. Epub 2022 Mar 10.
6
Receptor binding domain of SARS-CoV-2 from Wuhan strain to Omicron B.1.1.529 attributes increased affinity to variable structures of human ACE2.武汉株 SARS-CoV-2 的受体结合域与奥密克戎 B.1.1.529 相比,对人 ACE2 的可变结构具有更高的亲和力。
J Infect Public Health. 2022 Jul;15(7):781-787. doi: 10.1016/j.jiph.2022.06.004. Epub 2022 Jun 16.
7
Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2.病毒受体ACE2直系同源物的功能和遗传分析揭示了SARS-CoV-2广泛的潜在宿主范围。
Proc Natl Acad Sci U S A. 2021 Mar 23;118(12). doi: 10.1073/pnas.2025373118.
8
Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk.SARS-CoV-2 刺突突变的分子动力学模拟分析及宠物和野生动物 ACE2 感染风险评估。
Comput Biol Chem. 2022 Feb;96:107613. doi: 10.1016/j.compbiolchem.2021.107613. Epub 2021 Dec 1.
9
COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2.COVID-19 大流行:对 SARS-CoV-2 结构、功能和 hACE2 受体识别的深入了解。
PLoS Pathog. 2020 Aug 21;16(8):e1008762. doi: 10.1371/journal.ppat.1008762. eCollection 2020 Aug.
10
Mechanisms of COVID-19 pathogenesis in diabetes.COVID-19 发病机制在糖尿病中的研究进展。
Am J Physiol Heart Circ Physiol. 2022 Sep 1;323(3):H403-H420. doi: 10.1152/ajpheart.00204.2022. Epub 2022 Jul 1.

引用本文的文献

1
Investigating the Post-Mortem Risk of Transmission of SARS-CoV-2 Virus in Cadaveric Tissues: A Systematic Review of the Literature.研究严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒在尸体组织中的死后传播风险:文献系统综述
Microorganisms. 2025 Jan 27;13(2):284. doi: 10.3390/microorganisms13020284.
2
Current Updates on Variants of SARS-CoV- 2: Systematic Review.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株的最新情况:系统评价
Health Sci Rep. 2024 Nov 4;7(11):e70166. doi: 10.1002/hsr2.70166. eCollection 2024 Nov.
3
Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants.

本文引用的文献

1
Culture and identification of a "Deltamicron" SARS-CoV-2 in a three cases cluster in southern France.在法国南部的三例聚集性病例中培养并鉴定出一种“德尔塔-奥密克戎” SARS-CoV-2。
J Med Virol. 2022 Aug;94(8):3739-3749. doi: 10.1002/jmv.27789. Epub 2022 May 6.
2
Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells.细胞外中间丝相关蛋白是一种附着因子,可促进 SARS-CoV-2 进入人内皮细胞。
Proc Natl Acad Sci U S A. 2022 Feb 8;119(6). doi: 10.1073/pnas.2113874119.
3
Deltacron: the story of the variant that wasn't.
全面综述针对 SARS-CoV-2 变体的广泛中和抗体。
Viruses. 2024 Jun 1;16(6):900. doi: 10.3390/v16060900.
4
Properties and Mechanisms of Deletions, Insertions, and Substitutions in the Evolutionary History of SARS-CoV-2.SARS-CoV-2 进化史中缺失、插入和替换的特性和机制。
Int J Mol Sci. 2024 Mar 26;25(7):3696. doi: 10.3390/ijms25073696.
5
Genome sequence diversity of SARS-CoV-2 in Serbia: insights gained from a 3-year pandemic study.塞尔维亚新冠病毒的基因组序列多样性:一项为期三年的疫情研究所得见解
Front Microbiol. 2024 Feb 27;15:1332276. doi: 10.3389/fmicb.2024.1332276. eCollection 2024.
6
Bartonella infections are prevalent in rodents despite efficient immune responses.尽管啮齿动物有有效的免疫反应,但它们仍普遍感染巴尔通体。
Parasit Vectors. 2023 Sep 4;16(1):315. doi: 10.1186/s13071-023-05918-7.
7
The relationship between sublingual immunotherapy for allergic rhinitis and the risk of symptoms in patients with COVID-19 infection.舌下免疫疗法治疗变应性鼻炎与 COVID-19 感染患者症状风险之间的关系。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2236538. doi: 10.1080/21645515.2023.2236538.
8
Immunoinformatics Strategy to Develop a Novel Universal Multiple Epitope-Based COVID-19 Vaccine.开发新型基于多表位的通用型 COVID-19 疫苗的免疫信息学策略
Vaccines (Basel). 2023 Jun 12;11(6):1090. doi: 10.3390/vaccines11061090.
9
Enhanced stability of the SARS CoV-2 spike glycoprotein following modification of an alanine cavity in the protein core.修饰蛋白核心中的丙氨酸空腔可增强 SARS-CoV-2 刺突糖蛋白的稳定性。
PLoS Pathog. 2023 May 18;19(5):e1010981. doi: 10.1371/journal.ppat.1010981. eCollection 2023 May.
10
Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An Investigation.针对新冠病毒奥密克戎变异株的人源单克隆抗体的比较结合能力:一项研究。
Antibodies (Basel). 2023 Feb 23;12(1):17. doi: 10.3390/antib12010017.
德尔塔克戎:不存在的变异毒株的故事。
Nature. 2022 Feb;602(7895):19. doi: 10.1038/d41586-022-00149-9.
4
Notes from the Field: Early Evidence of the SARS-CoV-2 B.1.1.529 (Omicron) Variant in Community Wastewater - United States, November-December 2021.实地记录:2021年11月至12月美国社区废水中SARS-CoV-2 B.1.1.529(奥密克戎)变体的早期证据
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(3):103-105. doi: 10.15585/mmwr.mm7103a5.
5
Mutation bias reflects natural selection in Arabidopsis thaliana.突变偏向反映了拟南芥中的自然选择。
Nature. 2022 Feb;602(7895):101-105. doi: 10.1038/s41586-021-04269-6. Epub 2022 Jan 12.
6
SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.SARS-CoV-2 B.1.1.529(奥密克戎)变异株-美国,2021 年 12 月 1 日-8 日。
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1731-1734. doi: 10.15585/mmwr.mm7050e1.
7
Convergent use of phosphatidic acid for hepatitis C virus and SARS-CoV-2 replication organelle formation.磷脂酸在丙型肝炎病毒和 SARS-CoV-2 复制细胞器形成中的会聚用途。
Nat Commun. 2021 Dec 14;12(1):7276. doi: 10.1038/s41467-021-27511-1.
8
Omicron SARS-CoV-2 variant: What we know and what we don't.奥密克戎新冠病毒变种:我们所知道的和不知道的
Anaesth Crit Care Pain Med. 2022 Feb;41(1):100998. doi: 10.1016/j.accpm.2021.100998. Epub 2021 Dec 10.
9
Omicron emerges.奥密克戎出现了。
New Sci. 2021 Dec 4;252(3363):7. doi: 10.1016/S0262-4079(21)02140-0. Epub 2021 Dec 3.
10
Extracellular Vimentin as a Target Against SARS-CoV-2 Host Cell Invasion.细胞外波形蛋白作为抗 SARS-CoV-2 宿主细胞入侵的靶点。
Small. 2022 Feb;18(6):e2105640. doi: 10.1002/smll.202105640. Epub 2021 Dec 5.